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Summary.-Peripheral lymphocyte counts were performed on 41 patients with
advanced breast cancer, before starting treatment with oestrogens or androgens.
Patients were seen at monthly intervals, and the response to treatment was
independently assessed, using the criteria of the British Breast Group. In the
patients treated with oestrogens and androgens, the successful responders were
found to have significantly higher pre-treatment peripheral lymphocyte counts than
the intermediate responders and failures. It is suggested that pre-treatment
peripheral lymphocyte counts may have a prognostic value in assessing potential
response to hormone therapy in patients with breast cancer.
RECENTLY there has been considerable
interest in the significance of peripheral
lymphocyte counts as prognostic markers
in patients with breast cancer. In a
retrospective study, Papatestas and Kark
(1974) demonstrated a correlation be-
tween pre-treatment lymphocyte counts
and recurrence, particularly in Stage I
and Stage II patients. Those patients
free from recurrence at the end of 5 years
had significantly higher pre-treatment
counts than patients with recurrence.
In animal studies Franks, Bishop and
Perkins (1975) have shown that high
peripheral lymphocyte counts are also
associated with a stimulation in cell-
mediated immunity (CMI), whereas low
counts are associated with depressed
CMI. These changes in CMI were ini-
tiated by the administration of oestrogens
and androgens to male and female mice.
In the studies reported here, peripheral
lymphocyte counts were carried out in
patients with advanced breast cancer,
before treatment with oestrogens or andro-
gens. The response to treatment was
decided independently by two assessors,
who did not know the pre-treatment
lymphocyte counts. The criteria of the
British Breast Group (1974) were used.
PATIENTS AND METHODS
Patients.-Details of the 41 patients
studied are given in Table I.
The oestrogen-treated patients were over
5 years post-menopausal, and were given oral
stilboestrol (50 mg) or ethinyl oestradiol
(1 mg) daily. Androgen-treated patients were
within 5 years of the menopause, and were
given fluoxymesterone (Ultandren), the dose
being calculated according to body weight.
Patients < 60 kg received 10 mg twice
daily, and patients > 60 kg received 10 mg
3 times daily.
As soon as there was clinical evidence of
treatment failure, the patient was with-
drawn from the study, and the treatment was
changed.
Methods. Peripheral lymphocyte counts
were carried out on all patients inthe study,
before hormone treatment was started. A
differential total white blood count was
carried out on 100 cells as a routine investiga-
tion in the hospital haematology laboratory.
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Assessment method.-Patients were
assessed using the criteria of the British
Breast Group. Only patients with measur-
able improvement of all visible, palpable,
and radiological lesions for a period of at
least 6 months were considered to be success-
ful responders. In addition, no new lesions
must have appeared during this period.
Patients with a remission of less than
6 months or in whom the lesions were
unaltered by therapy or where theie was a
mixed response were classified as " inter-
mediate ". Patients with steadily worsening
lesions were considered to be treatment
failures.
Statistical analysis.-Comparison between
the log10 counts in each group was carried
out using Student's t test. This was done
to correct for the skew distribution of the
patient samples in the treatment response
groups. Successful responders (8) were com-
pared with the combined intermediate and
failure groups (I + F) to enable a comparison
to be made between patients in whom
hormones achieved a definite remission, and
patients in whom a mixed or negative
response occurred. P < 0 05 was considered
significant.
RESULTS
Table II shows the combined oestrogen
and androgen pre-treatment mean
lymphocyte counts, followed by the mean
counts obtained for each of the individual
treatment groups. In the combined
oestrogen and androgen analysis, the
difference in the pre-treatment lympho-
cyte counts between the successes and
the intermediates and failures is highly
significant (P < 0.001). If the oestrogen
and androgen treatment groups are
considered separately, the difference be-
tween the successes and the intermediates
and failures remains significant (oestrogen
P < 0.01, androgen P < 0.05).
Of the 41 patients studied, 31 had
received previous radiotherapy (DXT)
either as the sole primary treatment, or
following their primary operation. Two
of these were responders, and 14 were
amongst the intermediates and failures
in the oestrogen-treated group. One
patient who had been previously treated
with radiotherapy had a successful
response to androgen therapy and the
remaining 14 failed to respond or had an
intermediate response.
DISCUSSION
The results show that patients with
advanced breast cancer who respond
favourably to oestrogen or androgen
treatment have significantly higher pre-
treatment peripheral lymphocyte counts
than the intermediate and failure patients
in the same treatment groups.
Meyer (1970) has attributed the
lymphopenia often observed in patients
with breast cancer who have been treated
with radiotherapy, to the effects of
radiotherapy, and considers the lympho-
penia to reflect an induced defect in
cellular immunity. Such a depression in
CMI might help to explain why patients
in the intermediate and failure groups,
in both androgen- and oestrogen-treated
patients responded so badly. However,
the lymphopenia cannot be attributed
entirely to radiotherapy. Twenty-seven
per cent of oestrogen-treated patients, and
TABLE II. Pre-treatment Peripheral Lymphocyte Counts in Patients Treated with
Oestrogens and Androgens. Mean E s.d.
Success (S)
n Lymph. Ct.
4 2367
± 1009
2 2614
4 1363
6 2449
±999
Intermediate (I)
n Lymph. Ct.
11 1052
+ 396
5 1568
± 824
16 1214
+589
Failure (F)
n Lymph. Ct.
7 957
+163
12 842
±271
19 884
± 239
I + F
n Lymph. Ct.
18 1016
+ 322
17 1055
±580
35 1034
+459
Group
Oestrogen
Androgen
Total
Difference
(S) vs. (I+F)
P < 0.01
P < 0.05
P < 0-001
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21% of androgen-treated patients, did
not receive any radiotherapy, because
they were classified as having Stage I
carcinomas at the time of the primary
treatment. These patients aredistributed
throughout the 3 categories of treat-
ment response. There would therefore
appear to be no meaningful correlation
between primary radiotherapy and
peripheral lymphocyte counts in this
study.
In the animal studies of Franks et al.
(1975) potentiation of CMI occurred
following the administration of exo-
genous sex hormones, and non-hormone-
dependent tumours were rejected by the
mice. This potentiation was associated
with a rise in the peripheral lymphocyte
count. Conversely, a depressed count
was associated with a depression in CMI,
and survival of non-hormone-dependent
tumours.
In view of the above findings and the
observations of Meyer (1970), it is postu-
lated that the difference in the peripheral
lymphocyte counts between the successful
responders to oestrogens and androgens
and the intermediates and failures,
represents essentially different levels of
CMI. The fact that only patients with
high pre-treatment counts respond to
oestrogens and androgens, suggests that
these hormones may achieve at least
part oftheir effect in man by an immuno-
logical mechanism, as has been shown in
rodents.
To date, 11 patients treated by
oophorectomy have also been studied,
but only one has had a successful response.
The results suggest a converse relationship
between peripheral lymphocyte count
and response in these patients. The
successful responder had a count of 592
lymphocytes/,ul whereas the intermediates
plus failures had a mean count of 1774
lymphocytes/,ul (P = 002). Further
patients are currently being investigated.
The results of treatment with oestro-
gens and androgens in this study suggest
that pre-treatment peripheral lymphocyte
counts may have some value in assessing
the potential response of patients with
advanced breast cancer to hormone
therapy.
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